Free Trial

NovaBay Pharmaceuticals (NBY) Stock Forecast & Price Target

NovaBay Pharmaceuticals logo
$0.70 -0.01 (-1.04%)
(As of 02:30 PM ET)

NovaBay Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
1

Based on 1 Wall Street analysts who have issued ratings for NovaBay Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 1 analysts, 1 has given a buy rating for NBY.

Consensus Price Target

$0.85
21.15% Upside
According to the 1 analysts' twelve-month price targets for NovaBay Pharmaceuticals, the average price target is $0.85. The highest price target for NBY is $0.85, while the lowest price target for NBY is $0.85. The average price target represents a forecasted upside of 21.15% from the current price of $0.70.
Get the Latest News and Ratings for NBY and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for NovaBay Pharmaceuticals and its competitors.

Sign Up

NBY Analyst Ratings Over Time

TypeCurrent Forecast
11/22/23 to 11/21/24
1 Month Ago
10/23/23 to 10/22/24
3 Months Ago
8/24/23 to 8/23/24
1 Year Ago
11/22/22 to 11/22/23
Strong Buy
0 Strong Buy rating(s)
N/A N/A N/A
Buy
1 Buy rating(s)
N/A N/A N/A
Hold
0 Hold rating(s)
N/A N/A N/A
Sell
0 Sell rating(s)
N/A N/A N/A
Consensus Price Target$0.85N/AN/AN/A
Forecasted Upside21.15% UpsideN/AN/AN/A
Consensus Rating
Buy
N/AN/AN/A

NBY Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NBY Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

NovaBay Pharmaceuticals Stock vs. The Competition

TypeNovaBay PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.80
2.50
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside19.21% Upside26,931.53% Upside9.83% Upside
News Sentiment Rating
Neutral News

See Recent NBY News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/11/2024Ascendiant Capital Markets
2 of 5 stars
 Lower TargetBuy ➝ Buy$8.00 ➝ $0.85+19.75%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:52 PM ET.


NBY Forecast - Frequently Asked Questions

According to the research reports of 1 Wall Street equities research analysts, the average twelve-month stock price forecast for NovaBay Pharmaceuticals is $0.85, with a high forecast of $0.85 and a low forecast of $0.85.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NovaBay Pharmaceuticals in the last year. There is currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" NBY shares.

According to analysts, NovaBay Pharmaceuticals's stock has a predicted upside of 21.15% based on their 12-month stock forecasts.

NovaBay Pharmaceuticals has been rated by research analysts at Ascendiant Capital Markets in the past 90 days.

Analysts like NovaBay Pharmaceuticals more than other "medical" companies. The consensus rating for NovaBay Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how NBY compares to other companies.


This page (NYSE:NBY) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners